{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-221213","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.684627+00:00","generated_at":"2026-06-23T23:47:11.535375+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Forte Q2 net loss $3.0M; cash $38.5M; FB-102 on track for late 2023/early 2024","bullets":["Net loss $3.0M for Q2 2022 ($0.21 per share), compared to $5.8M loss ($0.43) in Q2 2021.","Cash and equivalents $38.5M as of June 30, 2022; raised $7.0M via ATM in July/August.","R&D spend down to $1.0M from $3.5M YoY as FB-401 wound down; focus shifting to autoimmune pipeline.","Lead candidate FB-102 expected to enter clinic late 2023 or early 2024 for GvHD, vitiligo, alopecia areata.","Appointed Hubert Chen as CSO and President; added Stephen Doberstein to board of directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-221213","json":"https://secwatch.observer/filing/0001193125-22-221213.json","markdown":"https://secwatch.observer/filing/0001193125-22-221213.md","text":"https://secwatch.observer/filing/0001193125-22-221213.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312522221213/0001193125-22-221213-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312522221213/d303551d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:47:11.535375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}